866-997-4948(US-Canada Toll Free)

Wilms Tumor (Nephroblastoma) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 54 Pages

Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma) Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape.

Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Wilms' Tumor (Nephroblastoma) Overview 6
Therapeutics Development 7
Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview 7
Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis 8
Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies 9
Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes 10
Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Wilms' Tumor (Nephroblastoma) - Products under Development by Companies 13
Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes 14
Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development 15
Exelixis Inc 15
NanoSmart Pharmaceuticals Inc 16
Recombio SL 17
Selvita SA 18
Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
cabozantinib s-malate - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Cellular Immunotherapy for Oncology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody Conjugate for Wilms' Tumor - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
racotumomab - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
SEL-12034 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Wilms' Tumor (Nephroblastoma) - Dormant Projects 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7
Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Wilms' Tumor (Nephroblastoma) - Pipeline by Exelixis Inc, H2 2016 15
Wilms' Tumor (Nephroblastoma) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 16
Wilms' Tumor (Nephroblastoma) - Pipeline by Recombio SL, H2 2016 17
Wilms' Tumor (Nephroblastoma) - Pipeline by Selvita SA, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Wilms' Tumor (Nephroblastoma) - Dormant Projects, H2 2016 52

List of Figures
Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016 7
Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Top 10 Targets, H2 2016 20
Number of Products by Stage and Top 10 Targets, H2 2016 20
Number of Products by Top 10 Mechanism of Actions, H2 2016 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *